E. I. du Pont de Nemours and Company
http://www.dupont.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From E. I. du Pont de Nemours and Company
Bracing For The Cold: Time For Korean Bioventures To Cut Down
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.
Korean Firms Hunt For Overseas Biologics Manufacturers To Support Growth
Korean companies, including large conglomerates and non-biopharmas, are increasingly jumping into biologics manufacturing through cross-border acquisitions following the successes of Samsung and SK.
Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
Was Apokyn Safety Update A Missed Opportunity For Supernus To Hold Off Generic Refill Cartridge?
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- DowDuPont
- DuPont